Dinesh V Patel, CEO - Protagonist Therapeutics (PTGX)
Dinesh V. Patel, Ph.D., is a distinguished leader in the biopharmaceutical industry, serving as the Director, President, and CEO of Protagonist Therapeutics (NASDAQ: PTGX). It is a clinical-stage biopharmaceutical company that improves patients’ lives through the power of peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate.Under Dr. Patel’s guidance, the company has been at the forefront of developing innovative peptide therapeutics designed to address critical medical needs. Dr. Patel has 38 years of executive, entrepreneurial, and scientific experience in the pharmaceutical, biotechnology and biopharmaceutical industries. Before joining Protagonist Therapeutics, he served as President and CEO of Arête Therapeutics from 2006 to 2008.
Earlier, he co-founded Miikana Therapeutics and was CEO from 2003 to 2005. Dr. Patel also held senior positions at Vicuron Pharmaceuticals, where he was Senior Vice President of Drug Discovery and Licensing from 1996 to 2003, contributing to the development of important marketed drugs such as anidulafungin and dalbavancin. His earlier career included roles as Director of Chemistry at Affymax (1993-1996) and as a Medicinal Chemist at Bristol-Myers Squibb from 1985 to 1993.
As CEO of Protagonist Therapeutics, Dr. Patel has overseen the development of multiple orally stable peptide-based drugs, including rusfertide, PN - 235, and PN - 943. These candidates are in various stages of clinical trials, targeting conditions such as polycythemia vera and ulcerative colitis, showcasing the company’s commitment to addressing unmet medical needs in rare and prevalent diseases.
“Our success stems from a diverse team of scientific and operational experts, whose expertise drives our discovery process and ability to advance assets from discovery to clinical development, with the goal of eventual approval,” says Dr. Patel.
He also played a key role in securing a strategic partnership with Janssen—a collaboration vital for advancing the development of PN-235. This alliance strengthens Protagonist Therapeutics' research capabilities and positions the company to achieve significant financial milestones, with substantial payments tied to clinical progress.
In a parallel vein, Dr. Patel strongly emphasizes building a company culture rooted in passion and collaboration. He believes fostering a transparent environment where team members can leverage their unique talents is essential to driving innovation and ensuring success in drug development. Over the years, he has consistently sought out strategic leaders who combine long-term vision with patience, humility, and the ability to evolve with the company’s changing needs. Dr. Patel also highlights that successful outcomes stem from the strength of diverse perspectives and backgrounds, fostering an environment where individuals are valued for their expertise and ability to collaborate effectively toward a shared goal.
“Our success stems from a diverse team of scientific and operational experts, whose expertise drives our discovery process and ability to advance assets from discovery to clinical development, with the goal of eventual approval,” says Dr. Patel.
He also played a key role in securing a strategic partnership with Janssen—a collaboration vital for advancing the development of PN-235. This alliance strengthens Protagonist Therapeutics' research capabilities and positions the company to achieve significant financial milestones, with substantial payments tied to clinical progress.
In a parallel vein, Dr. Patel strongly emphasizes building a company culture rooted in passion and collaboration. He believes fostering a transparent environment where team members can leverage their unique talents is essential to driving innovation and ensuring success in drug development. Over the years, he has consistently sought out strategic leaders who combine long-term vision with patience, humility, and the ability to evolve with the company’s changing needs. Dr. Patel also highlights that successful outcomes stem from the strength of diverse perspectives and backgrounds, fostering an environment where individuals are valued for their expertise and ability to collaborate effectively toward a shared goal.
"Our success stems from a diverse team of scientific and operational experts, whose expertise drives our discovery process and ability to advance assets from discovery to clinical development, with the goal of eventual approval. "
With three assets in advanced clinical development, Protagonist Therapeutics is well-positioned for significant breakthroughs in the biotechnology sector. The company is particularly optimistic about rusfertide, which promises to deliver a groundbreaking treatment for blood cancers like polycythemia vera. Under Dr. Patel's leadership, the focus remains firmly on innovating and developing new therapies, committed to efficiently delivering these treatments to patients in need.